secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001193125-25-179464
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Q2 2025 net loss $11.4M; Phase 1 TH103 data expected Q4 2025
--------------------------------------------------------------------

- Net loss $11.4M ($0.61/shr) vs $5.7M ($4.26/shr) in Q2 2024; no revenue in either period.
- Cash $88.4M at June 30, 2025 (up from $1.6M at Dec 31, 2024) after AlloVir merger.
- R&D expenses $8.4M (up from $3.2M YoY) driven by Phase 1 clinical trial initiation.
- Enrolling nAMD patients in Phase 1 trial of anti-VEGF TH103; initial data expected Q4 2025.
- Hired Kristine Curtiss as SVP of Clinical; over 25 years ophthalmology experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/0001193125-25-179464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer